HR 10628In Committee
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Introduced September 28, 2026
Summary
Timeline
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
See how this bill affects you
Enter your details to get a personalized impact estimate.
Check your impact